Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (February 2026)
27 slides from Sutro Biopharma's investor presentation, Feb 10, 2026
Slide 1: Sutro Biopharma February 2026
Exhibit 99.1 February 2026 NASDAQ: STRO
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Proprietary Platform Creates Best-in-Class ADCs
Proprietary Platform Creates Best-in-Class ADCs At the forefront of next-gen ADCs, with improved antibody, linker, and payload for superior safety and efficacy Dual-payload ADCs, with partnered and Single-payload ADCs for complex targets where wholly-owned programs, to overcome competition is limite
Slide 4: Differentiated Pipeline of Single- and Dual-Payload ADCs
Differentiated Pipeline of Single- and Dual-Payload ADCs SINGLE-PAYLOAD ADCs: DUAL-PAYLOAD ADCs: Focused on Complex Targets Overcome Resistance and Expressed Across Many Tumor Types Delay Progression STRO-227: STRO-004: STRO-006: PTK7-Targeting dpADC TF-Targeting ADC ITGB6-Targeting ADC Supercharge
Slide 5: Next-Generation ADCs Enabled by Sutro's Proprietary Platform
Next-Generation ADCs Enabled by Sutro’s Proprietary Platform
Slide 6: Designed to Deliver: Proprietary platform enables enhanced ADCs
Designed to Deliver: Proprietary platform enables enhanced ADCs Precision Versatility Scalability Same cell-free system from Site-specific conjugation Increased flexibility on linker- discovery to commercial using non-natural amino acids payload number, placement, scale with consistent quality and c
Slide 7: Sutro's Platform Designed to Optimize Every Component of the ADC
Sutro’s Platform Designed to Optimize Every Component of the ADC Expanding the therapeutic window to minimize toxicity and maximize efficacy 1 ANTIBODY ▸High throughput screening identifies Ab with ideal attributes 1 ▸Reduced ILD risk enabled by Fc-silent design PAYLOAD 2 ▸High DAR exatecans; stable
Slide 8: Platform Enables Industry-Leading ADC Exposure
Our Proprietary Platform Enables Industry-Leading ADC Exposure, a Key Driver of Safety and Efficacy Comparing ADC Exposure in NHPs at DAR16 ADCs Highest Non-Severely Toxic Dose 6,000 Total Ab (ng/mL) Site combo A Site combo B 100,000 5,000 Site combo C STRO-ADC DAR8 Site combo D STRO-ADC 10,000 4,00
Slide 9: STRO-004 Potential Best-in-Class Exatecan ADC Targeting Tissue Factor
STRO-004 Potential Best-in-Class Exatecan ADC Targeting Tissue Factor
Slide 10: STRO-004: Potent TF-Targeting Exatecan ADC
STRO-004: Potent TF-Targeting Exatecan ADC Engineered for Robust Exposure and Efficacy 50x preclinical exposure vs approved TF ADC 1 ANTIBODY 1 ▸Tumor targeting, does not interfere with TF biology ▸Fc-silent to reduce ILD risk 2 PAYLOAD ▸DAR 8; safely boosts potency ▸Drives efficacy in low-copy targ
Slide 11: Significant Unmet Need Across Large Oncology Patient Populations
Significant Unmet Need Across Large Oncology Patient Populations Incidence (U.S.) and relapsed/refractory ORR and OS benchmarks across select relevant tumor types Incidence (U.S.) and Relapsed/Refractory ORR and Current Standard of Care in R/R OS Benchmarks Across Select Relevant Tumor Types % ORR m
Slide 12: STRO-004: Favorable In Vitro Tolerability Profile vs. Approved TF ADC
STRO-004: Favorable In Vitro Tolerability Profile vs. Approved TF ADC Eye Inflammation Skin Toxicities STRO-004 Human Corneal Epithelial Cells Human Keratinocytes Reduced Bleeding Risk 50% 46% 40% 30% 20% 10% 1% 0% STRO-004 Tisotumab Up to 70% of Tivdak-treated STRO-004 (DAR8-exatecan) Approved TF A
Slide 13: STRO-004: Promising Anti-Tumor Activity in Multiple TF-Expressing Cancer Models
STRO-004: Promising Anti-Tumor Activity in Multiple TF-Expressing Cancer Models STRO-004 % Best Response in PDX Models of Solid Tumors 100 DCR: 28/30 ORR: 22/30 DCR: 28/30 (93%) STRO-004 ORR: 22/30 (73%) ORR CR PR SD 50 Cancer N (%) 11 11 4 HNSCC 17 0 0 (65) (65) (24) 5 3 2 2 NSCLC 7 (71) (43) (29)
Slide 14: Detailed Monotherapy Development Strategy: Phase 1 Trial Ongoing
Detailed Monotherapy Development Strategy: Phase 1 Trial Ongoing Dose level 2 cleared; cohort 3 dosed as of February 2026 Initial data expected in mid-2026 Move Forward with Dose Escalation Tumor type eligibility Recommended Dose(s) Advanced Solid Tumors with Tissue Factor Expression Selected for TF
Slide 15: STRO-006 Potential Best-in-Class Exatecan ADC Targeting Integrin-Beta 6
STRO-006 Potential Best-in-Class Exatecan ADC Targeting Integrin-Beta 6
Slide 16: STRO-006: Selective ITGB6-Targeting Exatecan ADC
STRO-006: Selective ITGB6-Targeting Exatecan ADC for Leading Tolerability and PK STRO-006 is designed for superior selectivity, safety and stability 1 ANTIBODY 1 ▸High affinity to ITGB6 without effect on TGFβ signaling ▸Fc-silent to reduce ILD risk 2 PAYLOAD ▸ High stable DAR (8) ▸ Potent anti-tumor
Slide 17: ITGB6 Expression has Unique Promise in NSCLC and Other Solid Tumors
ITGB6 Expression has Unique Promise in NSCLC as well as Other Common Solid Tumors STRO-006 is designed for monotherapy and combination use, expanding its therapeutic reach Incidence (U.S.) Across Select Relevant Tumor Types 40,000 75,000 150,000 200,000 TNBC HNSCC CRC Lung ITGβ6 expression assumptio
Slide 18: STRO-006 Superior Activity to Competitor ADCs in Preclinical Models
STRO-006 Has Shown Superior Activity to Competitor ADCs in Preclinical Models Expressing ITGB6 adeno NSCLC PDX (CTG-0743) Non-squamous NSCLC PDX, mut-EGFR Squamous NSCLC PDX, WT-EGFR Bladder CDX, SW780 H score: 136 (Seagen) SW780 (UCC) 1500 2500 2000 ITGB6-moderate 2000 1500 1000 1500 1000 1000 500
Slide 19: Superior Anti-Tumor Activity and Duration of Response Following a Single Dose of STRO-006
Superior Anti-Tumor Activity and Greater Duration of Response Following a Single Dose of STRO-006 in HNSCC PDX Models 200 % Best Response PDX Models of HNSCC 150 100 200 50 % Best Response in PDX Models of HNSCC 0 STRO-006 aITGB6 DAR4 MMAE ADC 150 20 40 60 DCR: 14/17 DCR: 11/17 -50 ORR: 12/17 * ORR:
Slide 20: Delivering Dual-Payloads: The Next Revolution in ADCs
Delivering Dual-Payloads: The Next Revolution in ADCs
Slide 21: Dual-Payload ADCs: Targeted Combination Therapy to Improve Outcomes
Dual-Payload ADCs: Targeted Combination Therapy to Improve Outcomes Combination treatment approaches have been shown to improve outcomes in oncology vs single agent chemotherapy and remain standard of care in many therapeutic areas Dual-Payload ADCs: Potential to Become Future Standard of Care • Ove
Slide 22: Proprietary Cell-Free Platform Positions Sutro at Forefront of Dual-Payload Innovation
Proprietary Cell-Free Platform Positions Sutro at the Forefront of Dual-Payload Innovation Topo1 x Tubulin Enables novel drug combinations and tuning of ratios with Multiple the broadest payload diversity to overcome tumor resistance Topo1 x DDRi Modalities and improve tolerability Topo1 x IO Tailor
Slide 23: Sutro's First Wholly-Owned Dual-Payload ADC Targeting PTK7
Sutro’s First Wholly-Owned Dual-Payload ADC Targeting PTK7 A clinically validated, pan-tumor target enriched on tumor-initiating cells • Broad expression across high-need indications and Breast Cancer Xenograft Model associated with poor prognosis • Anti-tumor clinical activity of an anti-PTK7 ADC
Slide 24: Sutro Dual-Payload ADC: Preclinical Tolerability Meets Single-Payload Benchmarks
Sutro Dual-Payload ADC: Preclinical Tolerability Meets Single- Payload Benchmarks Even with Added MMAE Payload Area Target Linker Payload DAR NHP HNSTD Highest Clinical Phase a Enhertu HER-2 GGFG Deruxtecan 8 30 mg/kg (Q3Wx3) Approved b Datroway Trop-2 GGFG Deruxtecan 4 10 mg/kg (Q3Wx5) Approved c M
Slide 25: Dual-Payload ADCs Have Overcome Resistance and Driven Tumor Regression
Dual-Payload ADCs Have Overcome Resistance and Driven Tumor Regression in Preclinical Models Dual-Payload ADC Induces Tumor Dual-Payload ADCs Have Improved In Vivo Regression After Sequential ADC Resistance Efficacy in an MTI-Resistant CRC Xenograft Model HCT-116 Tumor Growth Curves 10 mg/kg Enhertu
Slide 26: iADC: Dual-Payload ADC Combining Cytotoxin and Immune Stimulator
iADC: Dual-Payload ADC Combining Tumor-Targeted Delivery of a Cytotoxin and Immune Stimulator Strategic partnership with Astellas to deliver new treatment options for cold tumors and patients unresponsive to existing cancer immunotherapies Combining a cytotoxin and immune modulator gives potential t
Slide 27: Pipeline of Next-Generation Single- and Dual-Payload ADCs
Pipeline of Next-Generation Single- and Dual-Payload ADCs PHASE 3/ PROGRAM MODALITY/TARGET INDICATION DISCOVERY PRECLINICAL PHASE 1/1B PHASE 2 REGISTRATIONAL MILESTONES Initial Phase 1 data STRO-004 Tissue Factor ADC Solid Tumors expected mid-2026 IND submission STRO-006 Integrin αvβ6 Solid Tumors e
Sutro Biopharma — Investor Presentation (February 2026) on 6ix